bluebird bio (NASDAQ:BLUE) and Immatics (NASDAQ:IMTX) Head to Head Comparison

bluebird bio (NASDAQ:BLUE) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for bluebird bio and Immatics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bluebird bio	2	7	2	0	2.00
Immatics	0	0	4	1	3.20

bluebird bio currently has a consensus price target of $3.03, indicating a potential upside of 564.54%. Immatics has a consensus price target of $16.67, indicating a potential upside of 112.31%. Given bluebird bio’s higher probable upside, equities research analysts plainly believe bluebird bio is more favorable than Immatics.

Volatility & Risk

bluebird bio has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.

Institutional & Insider Ownership

87.4% of bluebird bio shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 1.4% of bluebird bio shares are owned by insiders. Comparatively, 3.3% of Immatics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares bluebird bio and Immatics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bluebird bio	-565.74%	-322.46%	-53.17%
Immatics	-47.94%	-15.90%	-9.38%

Valuation and Earnings

This table compares bluebird bio and Immatics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bluebird bio	$29.50 million	3.00	-$211.91 million	($1.87)	-0.24
Immatics	$115.50 million	8.11	-$104.98 million	($0.66)	-11.89

Immatics has higher revenue and earnings than bluebird bio. Immatics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Summary

Immatics beats bluebird bio on 12 of the 15 factors compared between the two stocks.

About bluebird bio

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company’s clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.